C4 Therapeutics, Inc. (CCCC)
Largest Insider Buys in Sector
CCCC Stock Price History Chart
CCCC Stock Performance
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Insider Activity of C4 Therapeutics, Inc.
Over the last 12 months, insiders at C4 Therapeutics, Inc. have bought $0 and sold $0 worth of C4 Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at C4 Therapeutics, Inc. have bought $185,613 and sold $31.6M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,667 shares for transaction amount of $31,735 was made by Koppikar Utpal (director) on 2023‑02‑08.
List of Insider Buy and Sell Transactions, C4 Therapeutics, Inc.
| 2023-02-08 | director | 5,667 0.0109% | $5.60 | $31,735 | -44.36% | |||
| 2022-04-12 | President & CEO | 10,000 0.0196% | $8.40 | $84,000 | -7.59% | |||
| 2022-01-04 | Sale | Chief Medical Officer | 30,000 0.0617% | $31.66 | $949,935 | -69.95% | ||
| 2021-12-17 | Sale | director | 1,510 0.0032% | $30.25 | $45,678 | -69.12% | ||
| 2021-11-19 | Sale | director | 1,510 0.0034% | $40.11 | $60,566 | -73.29% | ||
| 2021-10-15 | Sale | director | 1,510 0.0034% | $44.94 | $67,859 | -72.36% | ||
| 2021-10-01 | Sale | Chief Medical Officer | 30,000 0.0644% | $45.43 | $1.36M | -54.31% | ||
| 2021-09-27 | Sale | director | 3,700 0.0076% | $50.04 | $185,146 | -56.99% | ||
| 2021-09-24 | Sale | director | 6,030 0.0127% | $50.10 | $302,130 | -56.18% | ||
| 2021-09-23 | Sale | director | 38,360 0.079% | $50.41 | $1.93M | -56.89% | ||
| 2021-09-22 | Sale | director | 21,096 0.0435% | $50.10 | $1.06M | -55.96% | ||
| 2021-09-21 | Sale | director | 20,642 0.0426% | $50.14 | $1.03M | -55.74% | ||
| 2021-09-17 | Sale | director | 21,680 0.0448% | $50.05 | $1.08M | -55.30% | ||
| 2021-09-17 | Sale | director | 1,510 0.0031% | $49.89 | $75,334 | -55.30% | ||
| 2021-09-16 | Sale | director | 52,998 0.1074% | $48.65 | $2.58M | -54.79% | ||
| 2021-09-15 | Sale | director | 108,386 0.2237% | $48.82 | $5.29M | -53.81% | ||
| 2021-09-14 | Sale | director | 1,968 0.0041% | $50.02 | $98,434 | -54.13% | ||
| 2021-09-13 | Sale | director | 13,320 0.0276% | $50.07 | $666,948 | -54.30% | ||
| 2021-09-10 | Sale | director | 5,100 0.0107% | $50.00 | $255,022 | -53.58% | ||
| 2021-09-10 | Sale | Chief Legal Officer | 25,000 0.0289% | $27.49 | $687,250 | -53.58% |
Insider Historical Profitability
| Prokupets Elena | director | 31681 0.0449% | $3.99 | 0 | 14 | |
| Fisher Stewart | Chief Scientific Officer | 22744 0.0322% | $3.99 | 0 | 3 | |
| Crystal Adam | Chief Medical Officer | 15000 0.0212% | $3.99 | 0 | 5 | |
| Salter Malcolm | director | 10952 0.0155% | $3.99 | 1 | 8 | +39.65% |
| Hirsch Andrew | President & CEO | 10000 0.0142% | $3.99 | 1 | 0 | <0.0001% |
| Koppikar Utpal | director | 5667 0.008% | $3.99 | 1 | 0 | <0.0001% |
| MCKEE WILLIAM | Chief Financial Officer | 5263 0.0075% | $3.99 | 1 | 0 | +39.65% |
| COHEN MARC A | 5030 0.0071% | $3.99 | 1 | 0 | +39.65% | |
| Siegel Jolie | Chief Legal Officer | 0 0% | $3.99 | 0 | 2 |
Institutional Investor Ownership
| State Street | $58.44M | 10.4 | 7.15M | +4,503.94% | +$57.17M | <0.01 | |
| RA Capital Management, L.P. | $39.85M | 7.09 | 4.88M | 0% | +$0 | 0.04 | |
| Wasatch Advisors | $35.36M | 6.29 | 4.33M | -39.37% | -$22.96M | 0.19 | |
| Lynx1 Capital Management Lp | $29.7M | 5.28 | 3.63M | +15.96% | +$4.09M | 1.57 | |
| Commodore Capital, LP | $27.86M | 4.96 | 3.41M | -10.25% | -$3.18M | 0.11 | |
| The Vanguard Group | $23.86M | 4.24 | 2.92M | +46.05% | +$7.52M | <0.0001 | |
| Soleus Capital Management, L.P. | $20.09M | 3.57 | 2.46M | +33.93% | +$5.09M | 0.08 | |
| Balyasny Asset Management Llc | $19.9M | 3.54 | 2.44M | +42.9% | +$5.97M | 0.05 | |
| T. Rowe Price | $17.28M | 3.08 | 2.12M | -17.32% | -$3.62M | <0.01 | |
| Bank of America | $15.16M | 2.7 | 1.86M | +10.75% | +$1.47M | <0.01 | |
| Silverarc Capital Management Llc | $11.73M | 2.09 | 1.44M | New | +$11.73M | 0.12 | |
| Two Sigma Advisers LP | $10.72M | 1.91 | 1.31M | +1,704.95% | +$10.13M | 0.02 | |
| Arrowmark Colorado Holdings Llc | $10.56M | 1.88 | 1.29M | -39.55% | -$6.91M | 0.03 | |
| Goldman Sachs | $10.47M | 1.86 | 1.28M | +1,028.72% | +$9.54M | <0.01 | |
| Tcg Crossover Management Llc | $10.43M | 1.86 | 1.28M | 0% | +$0 | 0.02 | |
| Two Sigma | $9.57M | 1.7 | 1.17M | New | +$9.57M | 0.01 | |
| Bain Capital Life Sciences Investors Llc | $9.33M | 1.66 | 1.14M | -30.45% | -$4.09M | 0.75 | |
| Point72 Asset Management | $7.41M | 1.32 | 906,472 | -53.78% | -$8.62M | 0.01 | |
| BlackRock | $7.39M | 1.32 | 905,006 | -49.82% | -$7.34M | <0.0001 | |
| Rafferty Asset Management Llc | $6.81M | 1.21 | 833,681 | New | +$6.81M | 0.02 | |
| Citigroup | $6.3M | 1.12 | 770,728 | +468.92% | +$5.19M | 0.01 | |
| Cubist Systematic Strategies | $6.25M | 1.11 | 764,862 | +145.64% | +$3.7M | 0.06 | |
| UBS | $5.69M | 1.01 | 696,677 | +150.27% | +$3.42M | <0.01 | |
| Dimensional Fund Advisors | $5.16M | 0.92 | 632,091 | +447.23% | +$4.22M | <0.01 | |
| Millennium Management LLC | $4.7M | 0.84 | 575,131 | -21.45% | -$1.28M | <0.01 | |
| Laurion Capital Management LP | $4.37M | 0.78 | 535,342 | New | +$4.37M | 0.03 | |
| Morgan Stanley | $4.2M | 0.75 | 514,183 | +150.4% | +$2.52M | <0.0001 | |
| Geode Capital Management | $4.17M | 0.74 | 510,315 | +5.81% | +$229,045.97 | <0.0001 | |
| D. E. Shaw & Co. | $4.06M | 0.72 | 496,543 | +103.8% | +$2.07M | <0.01 | |
| Susquehanna International Group | $3.98M | 0.71 | 487,651 | -51.36% | -$4.21M | <0.01 | |
| Renaissance Technologies | $3.31M | 0.59 | 405,800 | -4.45% | -$154,395.02 | 0.01 | |
| Qube Research & Technologies | $3.17M | 0.56 | 388,193 | +1,332.97% | +$2.95M | <0.01 | |
| Citadel Advisors LLC | $2.73M | 0.49 | 334,518 | +608.51% | +$2.35M | <0.01 | |
| Atom Investors Lp | $2.58M | 0.46 | 316,246 | New | +$2.58M | 0.17 | |
| Charles Schwab | $2.18M | 0.39 | 267,429 | +5.82% | +$120,254.23 | <0.0001 | |
| Trexquant Investment LP | $1.83M | 0.33 | 224,487 | New | +$1.83M | 0.03 | |
| Wellington Management Company | $1.61M | 0.29 | 197,109 | New | +$1.61M | <0.0001 | |
| Connor Clark & Lunn Investment Management Ltd | $1.42M | 0.25 | 174,356 | +3.65% | +$50,147.48 | <0.01 | |
| Marshall Wace | $1.2M | 0.21 | 146,644 | -86.94% | -$7.98M | <0.01 | |
| Man Group Plc | $1.14M | 0.2 | 139,900 | -12.43% | -$162,297.05 | <0.01 | |
| Squarepoint Ops LLC | $1.12M | 0.2 | 136,827 | +197.29% | +$741,852.61 | <0.01 | |
| Mariner Llc | $1.05M | 0.19 | 128,037 | 0% | +$0 | <0.01 | |
| Profund Advisors Llc | $1.03M | 0.18 | 126,250 | New | +$1.03M | 0.03 | |
| Jump Financial Llc | $951,862.00 | 0.17 | 116,507 | New | +$951,862.00 | 0.01 | |
| Northern Trust | $887,899.00 | 0.16 | 108,678 | +<0.01% | +$8.17 | <0.0001 | |
| Engineers Gate Manager Lp | $852,678.00 | 0.15 | 104,367 | New | +$852,678.00 | 0.02 | |
| Harbor Capital Advisors Inc | $792,000.00 | 0.14 | 96,964 | +27.93% | +$172,916.13 | 0.1 | |
| Td Asset Management Inc | $758,176.00 | 0.14 | 92,800 | -1.7% | -$13,072.00 | <0.01 | |
| American Century Investments | $725,905.00 | 0.13 | 88,850 | +155.8% | +$442,128.03 | <0.0001 | |
| Arete Wealth | $696,084.00 | 0.12 | 85,200 | +18.17% | +$107,027.00 | 0.07 |